These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 28213802)

  • 1. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
    Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
    Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.
    Zhuo YJ; Xi M; Wan YP; Hua W; Liu YL; Wan S; Zhou YL; Luo HW; Wu SL; Zhong WD; Wu CL
    Int J Mol Med; 2015 Apr; 35(4):966-72. PubMed ID: 25647485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival.
    Huang TB; Dong CP; Zhou GC; Lu SM; Luan Y; Gu X; Liu L; Ding XF
    Int Urol Nephrol; 2017 May; 49(5):825-835. PubMed ID: 28188414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein regulator of cytokinesis 1 overexpression predicts biochemical recurrence in men with prostate cancer.
    Luo HW; Chen QB; Wan YP; Chen GX; Zhuo YJ; Cai ZD; Luo Z; Han ZD; Liang YX; Zhong WD
    Biomed Pharmacother; 2016 Mar; 78():116-120. PubMed ID: 26898432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ARRDC3 Inhibits the Progression of Human Prostate Cancer Through ARRDC3-ITGβ4 Pathway.
    Zheng Y; Lin ZY; Xie JJ; Jiang FN; Chen CJ; Li JX; Zhou X; Zhong WD
    Curr Mol Med; 2017; 17(3):221-229. PubMed ID: 28782483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy.
    Guan Y; Wu Y; Liu Y; Ni J; Nong S
    Prostate; 2016 Aug; 76(11):986-93. PubMed ID: 27040772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression.
    Peng S; Du T; Wu W; Chen X; Lai Y; Zhu D; Wang Q; Ma X; Lin C; Li Z; Guo Z; Huang H
    Urol Oncol; 2018 Aug; 36(8):366.e1-366.e9. PubMed ID: 29903461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced expression of SRPK2 contributes to aggressive progression and metastasis in prostate cancer.
    Zhuo YJ; Liu ZZ; Wan S; Cai ZD; Xie JJ; Cai ZD; Song SD; Wan YP; Hua W; Zhong W; Wu CL
    Biomed Pharmacother; 2018 Jun; 102():531-538. PubMed ID: 29587239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
    Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
    Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpressed Rce1 is positively correlated with tumor progression and predicts poor prognosis in prostate cancer.
    Huang L; Li M; Wang D; He J; Wu W; Zeng Q; Li J; Xiao M; Hu J; He Y; Li Y; Mai L; Liu W
    Hum Pathol; 2016 Jan; 47(1):109-14. PubMed ID: 26546252
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Cai C; Luo J; Liu Q; Liu Z; Zhao Y; Wu X; Yuegao Y; Lei Y; Lu J; Wang Y; Cai Z; Duan X; Lei M; Gu D; Liu Y
    Genet Test Mol Biomarkers; 2021 Feb; 25(2):131-139. PubMed ID: 33596143
    [No Abstract]   [Full Text] [Related]  

  • 12. Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer.
    Xu N; Chen HJ; Chen SH; Xue XY; Chen H; Zheng QS; Wei Y; Li XD; Huang JB; Cai H; Sun XL
    Medicine (Baltimore); 2016 Jul; 95(29):e4326. PubMed ID: 27442684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.
    Sun X; Yang Z; Zhang Y; He J; Wang F; Su P; Han J; Song Z; Fei Y
    Int J Clin Exp Pathol; 2015; 8(7):8394-401. PubMed ID: 26339409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
    Zhang X; Wang Y; Ning Y
    Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated expression of PTCD3 correlates with tumor progression and predicts poor prognosis in patients with prostate cancer.
    Huang Y; Jiang G; Liang X; Lan Z; Su Z; Wu H; Weng J; Jiang X
    Mol Med Rep; 2018 Oct; 18(4):3914-3922. PubMed ID: 30132530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer.
    Zhang W; Shu P; Wang S; Song J; Liu K; Wang C; Ran L
    Gene; 2018 Oct; 675():136-143. PubMed ID: 29966681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of transformer 2β expression in prostate cancer.
    Diao Y; Wu D; Dai Z; Kang H; Wang Z; Wang X
    Int J Clin Exp Pathol; 2015; 8(6):6967-73. PubMed ID: 26261585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of microRNA-126 expression with clinicopathological features and the risk of biochemical recurrence in prostate cancer patients undergoing radical prostatectomy.
    Sun X; Liu Z; Yang Z; Xiao L; Wang F; He Y; Su P; Wang J; Jing B
    Diagn Pathol; 2013 Dec; 8():208. PubMed ID: 24350576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of SOCSs in human prostate cancer and their association in prognosis.
    Zhu JG; Dai QS; Han ZD; He HC; Mo RJ; Chen G; Chen YF; Wu YD; Yang SB; Jiang FN; Chen WH; Sun ZL; Zhong WD
    Mol Cell Biochem; 2013 Sep; 381(1-2):51-9. PubMed ID: 23666742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased expression of myosin light chain MYL9 in stroma predicts malignant progression and poor biochemical recurrence-free survival in prostate cancer.
    Huang YQ; Han ZD; Liang YX; Lin ZY; Ling XH; Fu X; Cai C; Bi XC; Dai QS; Chen JH; He HC; Chen YR; Jiang FN; Zhong WD
    Med Oncol; 2014 Jan; 31(1):820. PubMed ID: 24338276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.